Do you want to read an article? Please log in or register.
Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
Migraine and Headache
Related content
Migraine and Headache
Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life
Expert Rev Neurother.
Tassorelli C, Tedeschi G, Sarchielli P, Pini LA, Grazzi L, Geppetti P, De Tommaso M, Aguggia M, Cortelli P, Martelletti P
doi: 10.1080/
RECOMMENDED
Migraine and Headache
Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
Cephalalgia.
Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, Raskin J, Pearlman EM, Kudrow D
doi: 10.1177/0333102419864132.
RECOMMENDED
Migraine and Headache
A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Headache.
Winner PK, Kabbouche M, Yonker M, Wangsadipura V, Lum A, Brin MF
doi: 10.1111/head.13754.
Migraine and Headache
FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
Headache.
Rothrock JF, Adams AM, Lipton RB, Silberstein SD, Jo E, Zhao X, Blumenfeld AM, FORWARD Study investigative group.
doi: 10.1111/head.13653.
Migraine and Headache
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
BMC Neurol.
Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL
doi: 10.1186/s12883-018-1193-2.
Migraine and Headache
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions
Cephalalgia.
Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ, Xue F, Picard H, Zhang F, Wang A, Zhou Y, Hong F, Klatt J, Mikol DD
doi: 10.1177/0333102419888222.
RECOMMENDED
Migraine and Headache
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
doi: 10.1177/0333102419835459.
Migraine and Headache
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
Headache
Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD
doi: 10.1111/head.14138
RECOMMENDED
Migraine and Headache
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
Neurology.
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK
doi: 10.1212/WNL.